Innovative Technology that Enables RNAi in Difficult to Transfect Cells
Poster Apr 27, 2015
Christina Yamada, Kathryn Robinson, Allison St. Amand, Zaklina Strezoska, Greg Wardle, Anastasia Khvorova, Devin Leake
Delivery remains one of the last barriers for applying RNA interference (RNAi) in clinically relevant cell lines. Investigations at Dharmacon have led to the development of an innovative molecule for delivery in a wide variety of cell types. These modified siRNAs have been found to effectively silence target genes in cell types that are typically difficult to transfect using standard delivery methods. We present data for multiple cell types including SH-SY5Y (neuroblastoma), Jurkat (T-cells), and primary neurons. This technology, Dharmacon™ Accell™ siRNA reagents, allows for functional genomic studies in pertinent cell types. Moreover, in some instances, cells can be continuously dosed with these siRNAs, thus enabling knockdown of any target gene of interest for extended durations.
For circulating cell free DNA (ccfDNA) to be used in cancer research successfully, workflow standardization is essential. Access this poster to discover tips on optimal workflow control, how to yield smaller ccfDNA fragments and the differences in quantification and qualification of ccfDNA.READ MORE
When there is a need to quickly analyze samples using a number of different PCR assays, it is likely that optimal conditions for each assay will not be the same. First, different assays often will require different annealing temperatures for their primers. In addition, amplicons may be designed to be of different lengths and therefore require varying durations of the extension step.READ MORE